MedTrace Logo

Effects of Genotypes on Interferon Signaling in Chronic Hepatitis C

NCT00876174 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-08-16

No results posted yet for this study

Summary

The objective of this pilot project is to investigate the prognostic criteria for sensitivity of Chronic Hepatitis C (CHC) Genotype 1, patients to IFNa treatment. Signal transduction in peripheral blood mononuclear cell (PBMC) of control groups will be compared with that of CHC patients. For this study, 20 patients with Hepatitis C virus (HCV) infection who are to undergo standard antiviral therapy and 10 healthy donors (significant others of the HCV subject) will be enrolled. Signal transduction will be studied in peripheral blood of CHC subjects before the treatment, after 1 and 3 months of treatment, and 4-6 months following the completion of treatment.

Conditions

  • Chronic Hepatitis C

Interventions

PROCEDURE

Blood sampling of peripheral blood mononuclear cells

Group 1, (Patients): PMBC (20 ml blood) to be drawn at baseline, weeks 4 and 12 during antiviral therapy and 24 weeks following the end of antiviral therapy

PROCEDURE

Blood draw, 20ml peripheral blood mononuclear cells

One time blood draw of 20 ml

Sponsors & Collaborators

  • University of Nebraska

    lead OTHER

Principal Investigators

  • Mark E Mailliard, MD · University of Nebraska

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-15
Primary Completion
2010-01-08
Completion
2010-01-08

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00876174 on ClinicalTrials.gov